Hepatitis Monthly

Published by: Kowsar

Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Telbivudine-Treated Patients With Chronic Hepatitis B

Rui Zhou 1 , 2 , Yuan-Ping Zhou 1 , * , Chun Lin 2 , Hai-bing Gao 2 , Shui-wen Huang 2 , Zu-xiong Huang 2 , Fang Sun 2 , Yong Lin 2 , Dong-qing Zhang 2 , Qing-feng Lin 2 , Wen Ao 2 and Chen Pan 2 , *
Authors Information
1 Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Infectious Disease Hospital, Meng Chao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, China
Corresponding Authors:
Article information
  • Hepatitis Monthly: December 2013, 13 (12); e15573
  • Published Online: December 23, 2013
  • Article Type: Brief Report
  • Received: October 24, 2013
  • Revised: November 24, 2013
  • Accepted: November 30, 2013
  • DOI: 10.5812/hepatmon.15573

To Cite: Zhou R, Zhou Y, Lin C, Gao H, Huang S, et al. Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Telbivudine-Treated Patients With Chronic Hepatitis B, Hepat Mon. 2013 ;13(12):e15573. doi: 10.5812/hepatmon.15573.

Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003; 362(9401): 2089-94[DOI][PubMed]
  • 2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4): 529-38[DOI][PubMed]
  • 3. Hepatitis B Fact sheet WHO/204. 2000;
  • 4. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005; 25 Suppl 1: 3-8[DOI][PubMed]
  • 5. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991; 32(3): 294-8[PubMed]
  • 6. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2004; 19(6): 670-5[DOI][PubMed]
  • 7. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1): 65-73[DOI][PubMed]
  • 8. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006; 101(8): 1797-803[DOI][PubMed]
  • 9. Yuan HJ, Yuen MF, Ka-Ho Wong D, Sablon E, Lai CL. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J Viral Hepat. 2005; 12(4): 373-9[DOI][PubMed]
  • 10. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005; 54(11): 1610-4[DOI][PubMed]
  • 11. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003; 37(6): 1309-19[DOI][PubMed]
  • 12. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351(15): 1521-31[DOI][PubMed]
  • 13. Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001; 12 Suppl 1: 119-29[PubMed]
  • 14. Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004; 40(3): 719-26[DOI][PubMed]
  • 15. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129(2): 528-36[DOI][PubMed]
  • 16. Bridges EG. 388 Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity. J Hepatol. 2006; 44
  • 17. Deng M, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, et al. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J. 2012; 9: 185[DOI][PubMed]
  • 18. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001; 34(4 Pt 1): 785-91[DOI][PubMed]
  • 19. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2006; 44(2): 422-31[DOI][PubMed]
  • 20. Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat. 2009; 16(3): 149-55[DOI][PubMed]
  • 21. Tillmann HL, McHutchison JG. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2008; 358(14): 1517[DOI][PubMed]
  • 22. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009; 136(2): 486-95[DOI][PubMed]
  • 23. Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, et al. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther. 2006; 11(6): 779-86[PubMed]
  • 24. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology. 2007; 46(6): 1695-703[DOI][PubMed]
  • 25. Cox DR. Regression models and life-tables. J R Stat Soc. 1972; 34: 187-220
  • 26. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989; 10(5): 761-3[PubMed]
  • 27. Marinos G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology. 1996; 24(5): 991-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader